FDA orders a class-wide anesthesia warning for GLP-1 drugs

The U.S. Food and Drug Administration formally required GLP-1 drugmakers to add new safety language about breathing stomach contents into the lungs during surgery. In a letter dated September 6, 2024, FDA notified Novo Nordisk under section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act of "new safety information" that the agency determined should be included in the labeling for glucagon-like peptide-1 receptor agonist (GLP-1 RA) products. The information concerns "the serious risk of pulmonary aspiration for patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation." ^[1]

Pulmonary aspiration happens when food, liquid or stomach contents enter the airway and lungs. It is a known hazard of anesthesia, which is why patients are typically told not to eat or drink for a set period before a procedure. GLP-1 medicines slow how fast the stomach empties, which is the reason this risk has drawn regulatory attention. The FDA letter itself does not spell out case counts, mechanism details or specific pre-procedure instructions, and those details are not in the document released here. ^[1]

How the change reached the label

The September 6 notification was the trigger, not the finish line. Novo Nordisk submitted a supplemental new drug application for Ozempic (semaglutide) injection dated and received October 4, 2024, with further email correspondence with FDA on October 11 and 16, 2024. FDA approved the supplement — NDA 209637/S-032 — in a letter electronically signed November 1, 2024 by Monika Houstoun, Pharm.D., M.P.H., Deputy Director for Safety in FDA's Division of Diabetes, Lipid Disorders, and Obesity. The agency said the supplement "provides for revisions to the labeling for Ozempic consistent with our September 6, 2024, letter." ^[1]

The approval letter describes where the new language sits. FDA added margin marks to the Prescribing Information to flag "Recent Major Changes," and it removed italics from the heading "Pulmonary Aspiration During General Anesthesia or Deep Sedation" in Section 6, Adverse Reactions, to match the label's formatting. The enclosed content of labeling covers the Prescribing Information, the Medication Guide and the Instructions for Use, meaning the patient-facing Medication Guide was part of the package. ^[1]

FDA also set deadlines for the company. Novo Nordisk had to submit the structured product labeling within 14 days so the updated label would be accessible from public labeling repositories, and had to amend pending supplements with labeling changes within the same window. Separately, all promotional materials that make claims about the drug "must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety-related information," with "prominent disclosure" of the new safety information; the company had 7 days to submit a statement of intent to comply. ^[1]

Why it matters for patients

The practical effect is informational. The September 6 letter applies to GLP-1 receptor agonist products as a class, so patients taking these medicines can expect the aspiration risk to be described in the Prescribing Information and reflected in patient-facing materials rather than left to word of mouth between clinicians. ^[1]

For someone on a GLP-1 who has surgery, a colonoscopy or another procedure scheduled, this is the kind of information that surgical and anesthesia teams weigh when planning fasting and sedation. The FDA document available here does not say what the label tells clinicians to do, whether it recommends pausing the medicine, or how long any recommended fasting period might be. Those specifics are not yet known from this source.

The letter also does not list which other products received the same September 6 notification, or the dates their labels were updated. It refers broadly to GLP-1 RA products while approving only the Ozempic supplement. ^[1]

What happens next

The Ozempic supplement was approved effective November 1, 2024, with the updated structured product labeling due within 14 days of that date — putting the public label update in mid-November 2024. ^[1] Updates to other GLP-1 labels would follow each manufacturer's own supplement timeline, which this document does not describe.